CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
In February 2020, Vyepti (eptinezumab) became the first quarterly infusion of a CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including the results of a large Phase 2b dose-ranging study in patients with chronic migraine and two Phase 3 trials – PROMISE 1 in episodic migraine and PROMISE 2 in chronic migraine.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
